130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
"HIV Preventive Vaccine" [CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC(2)120(B,MN)GNP (vCP1452)
3 Completed Candidate HIV Vaccine
Condition: HIV Infections
Intervention: Drug: VRC-HIVDNA016-00-VP
4 Completed A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2
5 Completed A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
6 Completed Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: pGA2/JS2 Plasmid DNA Vaccine
7 Completed Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)
Conditions: HIV Infections;   Pregnancy;   HIV Seronegativity
Intervention: Biological: gp160 Vaccine (MicroGeneSys)
8 Completed A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine LFn-p24 Administered by the Intramuscular (IM) Route in Healthy Adults
Condition: HIV Infections
Intervention: Biological: HIV LFn-p24
9 Active, not recruiting Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults
Condition: HIV Infections
Intervention: Biological: Ad5.ENVA.48 HIV-1 vaccine
10 Completed Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
11 Unknown  Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers
Condition: HIV Infections
Intervention: Biological: SCBaL/M9
12 Completed Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP
13 Active, not recruiting Antigenic Competition in HIV Preventive Vaccines
Condition: HIV Infections
Interventions: Biological: rAd5 Gag-Pol Env A/B/C;   Biological: rAd5 Gag-Pol
14 Completed A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers
Condition: HIV Infections
Interventions: Biological: APL 400-047;   Biological: ALVAC-HIV MN120TMG (vCP205);   Drug: Sargramostim
15 Active, not recruiting Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA-016-00-VP;   Biological: VRCHIVADV014-00-VP
16 Completed A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: gp160 Vaccine (Immuno-AG)
17 Unknown  Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: HIV-1 DNA vaccine with protein vaccine boost
18 Completed Determining an Effective Site (Groin Versus Arm) for Giving HIV Vaccines
Condition: HIV Infections
Intervention: Biological: TBC-3B
19 Completed A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160
Condition: HIV Infections
Interventions: Biological: Hepatitis B Vaccine (Recombinant);   Biological: gp160 Vaccine (MicroGeneSys)
20 Completed A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects
Condition: HIV Infections
Intervention: Biological: P3C541b Lipopeptide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years